Soft PAN BET Inhibitors for Local Inflammation Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for inflammatory, autoimmune, and fibrotic diseases are inadequate, often causing systemic side effects and poor patient compliance due to inefficacy and adverse reactions, particularly with corticosteroids.
Innovation Solution
Development of PAN BET inhibitors, specifically soft BET inhibitors, which are administered topically or locally to target multiple inflammatory pathways, reducing cytokines and minimizing systemic side effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If corticosteroids are used to treat inflammatory and autoimmune diseases, then anti-inflammatory efficacy is improved, but systemic side effects increase
Solution Approach 1:
The invention segments the treatment approach by using topical formulations that deliver BET inhibitors directly to the affected skin areas, rather than systemic corticosteroid administration. This localized delivery segmentates the therapeutic action from systemic exposure, maintaining anti-inflammatory efficacy at the target site while avoiding widespread systemic side effects.
Solution Approach 2:
The invention applies local quality by formulating BET inhibitors for topical application to specific affected areas. The drug is concentrated where needed (inflammatory lesions) rather than distributed systemically, creating high local efficacy while minimizing systemic harmful effects. The topical formulation ensures the drug acts locally on inflammatory pathways in the skin.
2Reliability
If current treatments are used for inflammatory diseases, then disease control is improved, but patient compliance deteriorates due to adverse reactions
Solution Approach 1:
The invention converts the limitation of topical application (potential for localized irritation) into a benefit by using BET inhibitors that specifically target inflammatory pathways without the broad immunosuppressive effects of corticosteroids. The harm of potent anti-inflammatory treatment is converted into benefit through selective mechanism of action that maintains efficacy while reducing adverse reactions, thereby improving compliance.
Solution Approach 2:
The invention changes the pharmacological parameter from corticosteroid-based immunosuppression to BET inhibitor-based transcriptional regulation. This parameter change maintains disease control efficacy while altering the side effect profile, making the treatment more acceptable to patients and improving long-term compliance.
3Object-affected harmful factors
If topical treatments are used to minimize systemic effects, then systemic side effects are reduced, but treatment efficacy deteriorates for severe conditions
Solution Approach 1:
The invention applies preliminary action by using topical BET inhibitors to prevent progression of inflammatory skin conditions before they become severe systemic diseases. Early intervention with localized treatment prevents the need for more aggressive systemic therapy, maintaining efficacy for moderate conditions while avoiding systemic side effects. The preliminary topical treatment addresses inflammation at the skin level before it escalates.
Data Source
AI summary
The present disclosure relates to methods for the treatment, amelioration, or prophylaxis of an inflammatory and/or an autoimmune disease or disorder or a disease or disorder related thereto (e.g., wounds, pigmentation or pigmentation related diseases and disorders, joint or joint related diseases and disorders, respiratory or respiratory related diseases or disorders; and fibrosis or fibrosis associated diseases and disorders) using soft BET inhibitors.